Study On Nitric Oxide And Nitric Oxide Synthase In Asthmatic Rats Model

ObjectiveAs a novel signal molecule, nitric oxide (NO) plays an important role in pathagenesis of asthma. Growing evidence suggests that inducible nitric oxide synthase (iNOS) is the main source of the high output of exhaled NO (FENO) in asthma, which correlates with the severity of asthma and eosinophilic inflammation. FENO is suggested to be a novel noninvasive biomarker reflecting the control of asthma deterioration. Endothelial nitric oxide synthase (eNOS) plays a protective role in physiological condition. It is regarded that allergic asthma is related to the down-regulating of eNOS and up-regulating of iNOS. Cysteinyl- leukotrienes (cys-LTs) are other inflammatory mediators in asthma. Montelukast (MK) is a cys-LTs receptor antagonist(cys-LTRA) and a new non-steroid anti-inflammation drug, which can significantly inhibit inflammation of airway and production of Th2 cytokines and expression of inflammatory genes, facilitate eosinophils apoptosis and attenuate airway hyperresponsiveness of patients with asthma . Glucocorticoids are now used as first-line drugs for the treatment of asthma, but they cannot inhibit the synthase and action of LTs. Therefore, as novel drug to treat asthma in clinic, MK has been demonstrating a...